1. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin.
- Author
-
Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, and Blagosklonny MV
- Subjects
- Antineoplastic Agents therapeutic use, Benzamides, Benzoquinones, Cell Survival drug effects, Clone Cells, Drug Interactions, Drug Resistance, Neoplasm, Flavonoids pharmacology, Flavonoids therapeutic use, HL-60 Cells, HSP70 Heat-Shock Proteins metabolism, HSP90 Heat-Shock Proteins metabolism, Humans, Imatinib Mesylate, K562 Cells, Lactams, Macrocyclic, Models, Biological, Piperazines therapeutic use, Piperidines pharmacology, Piperidines therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Pyrimidines therapeutic use, Quinones therapeutic use, Time Factors, Antineoplastic Agents pharmacology, Fusion Proteins, bcr-abl metabolism, Piperazines pharmacology, Proto-Oncogene Proteins c-raf metabolism, Pyrimidines pharmacology, Quinones pharmacology
- Abstract
By activating anti-apoptotic factors (e.g., Hsp70, Raf-1, Bcl-xL), Bcr-Abl blocks apoptotic pathways at multiple levels, thus rendering leukemia cells resistant to chemotherapeutic agents such as doxorubicin (DOX). In Bcr-Abl-transfected HL60 (HL/Bcr-Abl) cells, procaspase-9 was increased and partially processed. The Bcr-Abl inhibitor imatinib (Gleevec, STI-571) released the apoptotic stream. Also, HL/Bcr-Abl cells were hyper-sensitive to geldanamycin (GA), which depletes Bcr-Abl and Raf-1. Raf-1 and Bcr-Abl-transfected FDC-P1 hematopoietic cells were selectively sensitive to GA and imatinib, respectively. Remarkably, cell clones with high levels of Bcr-Abl that could not be depleted by GA were relatively resistant to both GA and imatinib. GA and flavopiridol sensitized such resistant cells to imatinib. These data suggest bi-phasic sensitivity to mechanism-based therapeutic agents. Although Bcr-Abl renders cells hyper-sensitive, an excess of Bcr-Abl results in resistance (due to the remaining activity). We discuss therapeutic approaches to overcome bi-phasic resistance to mechanisms-based agents.
- Published
- 2005
- Full Text
- View/download PDF